Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation

Estrogen receptor alpha (ERα)-positive breast cancers are frequently treated with tamoxifen, but resistance is common. It remains elusive how tamoxifen resistance occurs and predictive biomarkers for treatment outcome are needed. Because most biomarker discovery studies are performed using pre-treat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Severson, Tesa M., Nevedomskaya, Ekaterina, Peeters, Justine, Kuilman, Thomas, Krijgsman, Oscar, van Rossum, Annelot, Droog, Marjolein, Kim, Yongsoo, Koornstra, Rutger, Beumer, Inès, Glas, Annuska M., Peeper, Daniel, Wesseling, Jelle, Simon, Iris M., Wessels, Lodewyk, Linn, Sabine C., Zwart, Wilbert
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5085127/
https://ncbi.nlm.nih.gov/pubmed/27129152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8983
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi